Hormonal
Chronic obesity causes adipose tissue dysfunction through a triad of unresolved inflammation, fibrosis, and impaired angiogenesis, driven by persistent hypoxia and adipocyte death.
Obesity is not just about having too much fat; it is about the fat tissue becoming sick due to lack of oxygen, inflammation, and scarring. Simply losing weight might not fix these underlying tissue issues if the diet and lifestyle don't support healthy tissue remodeling. Focus on strategies that improve metabolic health and reduce inflammation, not just scale weight.
There are three dominant contributors to the pathogenesis of dysfunctional adipose tissue (AT) in obesity: unresolved inflammation, inappropriate extracellular matrix (ECM) remodeling and insufficient angiogenic potential.
Why this rating
High-quality review of multiple human and rodent studies, though it is a narrative review rather than a single primary trial.
Source
The ominous triad of adipose tissue dysfunction: inflammation, fibrosis, and impaired angiogenesis
Clair Crewe et al. · Journal of Clinical Investigation · 2017
DOI 10.1172/jci88883
More from this paper
- Hypoxia in expanding adipose tissue drives a complex response involving both pro-angiogenic and pro-fibrotic pathways, with HIF-1α playing a dominant pro-fibrotic role in obesity.Good
- Cellular senescence in adipose tissue contributes to obesity-associated dysfunction through the secretion of pro-inflammatory factors (SASP) and impairment of angiogenesis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →